da Vinci 5
The newest da Vinci generation accounted for 246 of the 468 systems placed in Q2 2026 and is now sold in Japan and Europe.
The numbers
What it is
da Vinci 5 is the newest generation of the da Vinci platform, with more computing power and new instrument options. It is the company's main growth vehicle for placements, and it is being rolled out in the United States and internationally as clearances come in.
Why it matters to the stock. The placement mix toward da Vinci 5 shows whether hospitals are upgrading and whether Intuitive can keep its share in each market.
News
da Vinci 5 receives CE mark for adult cardiac surgery in Europe
The da Vinci 5 system has received a CE mark for adult cardiac surgery in Europe, including coronary artery bypass procedures, according to trade press reporting on September 25, 2026.
Intuitive introduces da Vinci 5 in India with a focused rollout
Intuitive announced a focused introduction of da Vinci 5 in India, letting selected hospitals and programs build experience with the platform.
Intuitive rolls out more than 100 da Vinci 5 upgrades, starting in the U.S. in June
Intuitive announced more than 100 updates and user-experience improvements for da Vinci 5.
Intuitive Q1 2026 revenue up 23% to $2.77 billion; raises 2026 procedure and margin guidance
Intuitive reported first-quarter 2026 revenue of $2.77 billion, up 23%, with non-GAAP EPS of $2.50 and GAAP EPS of $2.28.
FDA clears da Vinci 5 for selected thoracoscopic cardiac procedures
The FDA cleared the da Vinci 5 system through a 510(k) for selected thoracoscopically assisted cardiac procedures, including mitral valve repair and internal mammary artery mobilization.
Intuitive reports Q4 2025 revenue up 19% and guides 2026 da Vinci procedures 13% to 15%
Intuitive reported fourth-quarter 2025 revenue of $2.87 billion, up 19%, with non-GAAP EPS of $2.53 and GAAP EPS of $2.21.